G1SK34:BVMF
GlaxoSmithKline
50,50 BRL
0,00%
(0,00) 1 d.
16. 10., 16:56:00 GMT-3 · BRL
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre G1SK34…
Otvoriť
50,10 BRL
Vysoká
50,75 BRL
Nízka
50,10 BRL
Trh. kap.
100,71 mld.
Priem. obj.
214,00
Objem
165,00
Max. za 52 týž.
63,24 BRL
Min. za 52 týž.
46,15 BRL
Akcie v obehu
4,32 mld.
Počet zamestnancov
67 tis.
Otvoriť
50,10 BRL
Vysoká
50,75 BRL
Nízka
50,10 BRL
Trh. kap.
100,71 mld.
Priem. obj.
214,00
Objem
165,00
Max. za 52 týž.
63,24 BRL
Min. za 52 týž.
46,15 BRL
Akcie v obehu
4,32 mld.
Počet zamestnancov
67 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
The Globe and Mail
·
pred 1 dňom
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Traders Union
·
pred 2 dňami
GSK shares technical analysis: Overbought conditions highlight reversal setup
JournalArta
·
pred 2 dňami
GSK Stock Gains 2.89% on Thursday: Full Details
Yahoo Finance
·
pred 2 dňami
Better Dividend Stock: Pfizer vs. GSK
Profil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Informácie o subjekte GlaxoSmithKline
Generálny riaditeľEmma Walmsley | Emma Walmsley
Zamestnanci66,8 tis.
Dátum založenia27. 12. 2000
Hlavné sídlo-
Odvetvie-
Webgsk.com